-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sanofi today announced that an analysis of data from the latest clinical trial of nirsevimab, a long-acting antibody therapy for respiratory syncytial virus (RSV), shows that in children entering their first RSV season, nirsevimab will reduce the need for treatment due to RSV infecti.
RSV is a common infectious agent that causes seasonal epidemics of LRTI, including bronchitis and pneumonia, and is the leading cause of hospitalization in infants worldwi.
This pre-specified meta-analysis pooled data from the pivotal Phase 3 clinical trial MELODY and the Phase 2b clinical tri.
Another post hoc analysis found that nirsevimab-treated infants had blood levels of RSV-neutralizing antibodies 50 times higher than baseline levels after 151 da.
"RSV remains the most common cause of LRTI in infants, causing seasonal epidemics each ye.
References:
[1] Press Release: New nirsevimab data analyses reinforce efficacy against R.